Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies
Cancer Immunology, Immunotherapy · 18.12.2025 · 75 (1)
DOI: 10.1007/s00262-025-04247-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.12.2025. Verfasst von Yi Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. Hauptthemen laut MEDLINE: Thalidomide, Tumor Microenvironment, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundamental Research Funds for Central Universities of the Central South University, National Natural Science Foundation of China, Beijing Medical and Health Foundation.
Abstract (Originalsprache)
BACKGROUND: Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, an immunomodulatory drug (IMiD), demonstrates clinical synergy with CAR-T therapy, yet the underlying mechanisms driving this potentiation remain poorly defined. This study aimed to elucidate how pomalidomide enhances CAR-T cell function and remodels the immune microenvironment to overcome therapeutic limitations. METHODS: In vitro assays (CCK-8, LDH, qPCR, ELISA, flow cytometry) and bulk RNA-seq assessed pomalidomide's effects on human CAR-T cells. In vivo efficacy was evaluated in myeloma xenograft models. Single-cell RNA sequencing (scRNA-seq) of PBMCs from a lymphoma patient post-CAR-T/pomalidomide assessed immune microenvironment remodeling. RESULTS: Pomalidomide significantly enhanced CAR-T cell proliferation and cytotoxicity in an activation-dependent manner. It upregulated effector molecules (IL-2, IFN-γ) and chemokines (CXCL9-CXCL11), promoted central memory T cells (Tcm), and induced metabolic reprogramming while reducing exhaustion markers. In xenografts, combination therapy induced tumor regression and extended survival vs. CAR-T alone. scRNA-seq revealed pomalidomide-driven remodeling, characterized by increased T/NK cell proportions/activity and reduced myeloid-derived suppressor cell (MDSC) signatures. CONCLUSIONS: Pomalidomide synergizes with CAR-T by directly enhancing CAR-T function (memory, cytokine/chemokine production, metabolic fitness, and reduced exhaustion) and remodeling the suppressive immune microenvironment (increased cytotoxic effectors, diminished MDSC activity). These findings provide a crucial mechanistic rationale for optimizing pomalidomide-CAR-T combinations in refractory lymphoid malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
- Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. anniezhc@163.com.
- Department of Hematology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. lixiner1975@163.com.
Förderung
- Fundamental Research Funds for Central Universities of the Central South University
- National Natural Science Foundation of China
- Beijing Medical and Health Foundation
Zitieren
APA
Zhou, Y., Yu, Y., Xie, L., Wang, L., Yan, Y., Cheng, Q., Liu, J., Zhang, C., & Li, X. (2025). Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies. Cancer Immunology, Immunotherapy, 75(1). https://doi.org/10.1007/s00262-025-04247-1
Vancouver
Zhou Y, Yu Y, Xie L, Wang L, Yan Y, Cheng Q, et al. Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies. Cancer Immunology, Immunotherapy. 2025;75(1). doi:10.1007/s00262-025-04247-1
BibTeX
@article{Zhou2025,
author = {Zhou, Yi and Yu, Yan and Xie, Linzhi and Wang, Liwen and Yan, Yuhan and Cheng, Qian and Liu, Jing and Zhang, Chang and Li, Xin},
title = {Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {75},
number = {1},
doi = {10.1007/s00262-025-04247-1}
}
EUVIMED